Designed to deliver confidence and reliability for diagnostic development and testing, the Applied Biosystems TaqPath PCR kits for infectious diseases such as Multi-Drug Resistant Tuberculosis (MTB MDR), M. Tuberculosis complex (MTB), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and for genetic analysis (HLA B27), have received licensing rights by the Central Drugs Standard Control Organisation (CDSCO) and will be manufactured in India in association with Pune-based Mylab Discovery Solutions.

The Applied Biosystems TaqPath PCR kits by Thermo Fisher have been analytically- and clinically-validated for use in patient care for disease screening and diagnosis, monitoring of therapeutic response and disease progression, and identification of genetic risk factors.

“Over the years, India has made significant progress in addressing infectious diseases such as Hepatitis B and C, HIV, and Tuberculosis. The country has implemented large-scale vaccination and treatment programs, as well as invested in research to better understand the epidemiology of these diseases and develop new diagnostic tools. However, India still faces challenges in controlling the spread of these diseases", said Jagjit Singh Anthak, Director, Genetic Sciences Group and Specialty Diagnostics Group, Thermo Fisher Scientific.

Hasmukh Rawal, Managing Director at Mylab Discovery Solutions said, “Laboratories in India and globally rely on the innovative products from Thermo Fisher, will now also benefit with a much wider range of quality diagnostic tests. Also, we would be assisting in tools for analysis of data to help labs make accurate results to their customers. This is a milestone moment in Indian diagnostics.”